As a result, these SNPs could serve as predictors of treatment response and may be associated with increased mortality in patients with advanced NSCLC.21 It has been suggested that rs11615 (ERCC1) and rs3738948 (ERCC3) can influence the efficacy of platinum-based chemotherapy in NSCLC patients.29 On the other hand, some studies have failed to find a significant relationship between ERCC1 gene polymorphisms and treatment efficacy in NSCLC patients receiving cisplatin-based chemotherapy. This evidence concerns the gene ERCC3 and non-small cell lung carcinoma.